Novartis's FSHD drug (del-brax) meets Phase I/II biomarker endpoints, advancing potential first-in-class treatment.
NVS sits 35% above its 52-week low of $112.34 on light trading volume (0.4× avg).
Summary
Novartis's investigational drug del-brax achieved positive Phase I/II results for FSHD, demonstrating potential as the first disease-modifying treatment for the rare neuromuscular disorder.
Key Events · Product Development and Regulatory · NVS
-
Positive Phase I/II Results
Delpacibart braxlosiran (del-brax) met primary and key secondary biomarker endpoints in the FORTITUDE Phase I/II study for facioscapulohumeral muscular dystrophy (FSHD), showing reductions in KHDC1L and creatine kinase levels.
-
Potential First-in-Class Treatment
Del-brax indicates potential to become the first disease-modifying treatment for FSHD, a progressive and irreversible neuromuscular disease affecting 45-87k people in the US and EU, which currently has no approved therapies.
-
Advancing Regulatory Pathway
Novartis plans to engage global regulatory authorities on the Phase I/II data. Del-brax has FDA Orphan Drug and Fast Track designations, and a Phase III study is currently enrolling.
-
Validation of Strategic Acquisition
Del-brax is a key asset acquired through the Avidity Biosciences acquisition, completed in February 2026, and these positive results validate that strategic investment.
Analysis · NVS · Life Sciences
Novartis announced positive Phase I/II results for del-brax, a potential first-in-class treatment for facioscapulohumeral muscular dystrophy (FSHD). The study met its primary and key secondary biomarker endpoints, showing strong target engagement and reduced muscle damage. This validates a key asset from the recent Avidity Biosciences acquisition and positions del-brax, which has Orphan Drug and Fast Track designations, for continued Phase III development in a disease with no approved therapies.
At the time of this filing, NVS was trading at $151.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $271.8B. The 52-week trading range was $112.34 to $170.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.